Is Mono Pharmacare overvalued or undervalued?

Sep 17 2025 08:06 AM IST
share
Share Via
As of September 16, 2025, Mono Pharmacare is considered overvalued with a PE ratio of 14.58 and a year-to-date return of -29.58%, especially when compared to peers like Sun Pharma and Divi's Lab, which are much more expensive.
As of 16 September 2025, Mono Pharmacare's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued based on its key ratios, including a PE ratio of 14.58, an EV to EBITDA ratio of 12.83, and a PEG ratio of 0.55. These figures suggest that the stock may not offer sufficient growth potential relative to its price.

In comparison to its peers, Mono Pharmacare's PE ratio is significantly lower than that of Sun Pharma (33.64) and Divi's Lab (70), both categorized as very expensive. However, it is also lower than the attractive valuations of Cipla (23.31) and Dr. Reddy's Labs (19.25). The recent stock performance has been notably poor, with a year-to-date return of -29.58%, contrasting sharply with the Sensex's positive return of 6.74% over the same period, reinforcing the notion that Mono Pharmacare is currently overvalued.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Why is Mono Pharmacare falling/rising?
Dec 13 2025 01:24 AM IST
share
Share Via
How has been the historical performance of Mono Pharmacare?
Nov 28 2025 10:44 PM IST
share
Share Via
Why is Mono Pharmacare falling/rising?
Nov 20 2025 12:18 AM IST
share
Share Via
How has been the historical performance of Mono Pharmacare?
Nov 18 2025 11:03 PM IST
share
Share Via
Is Mono Pharmacare overvalued or undervalued?
Nov 11 2025 08:14 AM IST
share
Share Via
Is Mono Pharmacare overvalued or undervalued?
Nov 07 2025 08:14 AM IST
share
Share Via
Why is Mono Pharmacare falling/rising?
Oct 16 2025 12:03 AM IST
share
Share Via
Most Read
Galada Finance Ltd is Rated Sell
21 minutes ago
share
Share Via
Gujarat Cotex Ltd is Rated Sell
21 minutes ago
share
Share Via
Beryl Drugs Ltd is Rated Sell
21 minutes ago
share
Share Via
Nutech Global Ltd is Rated Hold
21 minutes ago
share
Share Via